|
|
Vaccine Detail
|
pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine |
| Vaccine Information |
- Vaccine Name: pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007061
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- E7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Cervical Cancer (NCT00121173). An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death (Qiu et al., 2018; NCIT_C48418).
|
| Host Response |
|
|
| References |
NCIT_C48418: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48418]
NCT00121173: [https://clinicaltrials.gov/show/NCT00121173]
Qiu et al., 2018: Qiu J, Peng S, Ma Y, Yang A, Farmer E, Cheng MA, Roden RBS, Wu TC, Chang YN, Hung CF. Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination. Virology. 2018; 525; 205-215. [PubMed: 30296681].
|
|
